An Open, Parallel, Single-dose Phase I Clinical Study to Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency
Latest Information Update: 07 Nov 2024
Price :
$35 *
At a glance
- Drugs Avibactam/meropenem (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 07 Nov 2024 New trial record